Meta-analysis of recurrence pattern after resection for pancreatic cancer
2019/08/27 by Masayuki Tanaka, M Tanaka, André L. Mihaljević +13 · 26 citations
Medicine · #Pancreatic and Hepatic Oncology Research #Cholangiocarcinoma and Gallbladder Cancer Studies #Cancer Cells and Metastasis
paper · doi:10.1002/bjs.11295
Abstract
BACKGROUND: Initial recurrence mapping of resected pancreatic ductal adenocarcinoma (PDAC) could help in stratifying patient subpopulations for optimal postoperative follow-up. The aim of this systematic review and meta-analysis was to investigate the initial recurrence patterns of PDAC and to correlate them with clinicopathological factors. METHODS: MEDLINE and Web of Science databases were searched systematically for studies reporting first recurrence patterns after PDAC resection. Data were extracted from the studies selected for inclusion. Pooled odds ratios (ORs) and 95 per cent confidence intervals were calculated to determine the clinicopathological factors related to the recurrence sites. The weighted average of median overall survival was calculated. RESULTS: Eighty-nine studies with 17 313 patients undergoing PDAC resection were included. The weighted median rates of initial recurrence were 20·8 per cent for locoregional sites, 26·5 per cent for liver, 11·4 per cent for lung and 13·5 per cent for peritoneal dissemination. The weighted median overall survival times were 19·8 months for locoregional recurrence, 15·0 months for liver recurrence, 30·4 months for lung recurrence and 14·1 months for peritoneal dissemination. Meta-analysis revealed that R1 (direct) resection (OR 2·21, 95 per cent c.i. 1·12 to 4·35), perineural invasion (OR 5·19, 2·79 to 9·64) and positive peritoneal lavage cytology (OR 5·29, 3·03 to 9·25) were significantly associated with peritoneal dissemination as initial recurrence site. Low grade of tumour differentiation was significantly associated with liver recurrence (OR 4·15, 1·71 to 10·07). CONCLUSION: Risk factors for recurrence patterns after surgery could be considered for specific surveillance and treatments for patients with pancreatic cancer.
Cited by
- Periarterial divestment in pancreatic cancer surgery
- A Prognostic Prediction Model Developed Based on Four CpG Sites and Weighted Correlation Network Analysis Identified DNAJB1 as a Novel Biomarker for Pancreatic Cancer. [europepmc]
- Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review. [europepmc]
- The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. [europepmc]
- Significance of pulmonary resection in patients with metachronous pulmonary metastasis from pancreatic ductal adenocarcinoma: a retrospective cohort study. [europepmc]
- Hepatic Artery Infusion of Floxuridine in Combination With Systemic Chemotherapy for Pancreatic Cancer Liver Metastasis: A Propensity Score-Matched Analysis in Two Centers. [europepmc]
- Late recurrences of pancreatic cancer in patients with long-term survival after pancreaticoduodenectomy. [europepmc]
- Identification of prognostic lipid droplet-associated genes in pancreatic cancer patients via bioinformatics analysis. [europepmc]
- Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma. [europepmc]
- Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression. [europepmc]
- Cellular and molecular mechanisms of perineural invasion of pancreatic ductal adenocarcinoma. [europepmc]
- Lipid Droplet-Associated Factors, PNPLA3, TM6SF2, and HSD17B Proteins in Hepatopancreatobiliary Cancer. [europepmc]
- Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. [europepmc]
- Cancer-Associated Fibroblasts and Tumor Cells in Pancreatic Cancer Microenvironment and Metastasis: Paracrine Regulators, Reciprocation and Exosomes. [europepmc]
- A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells. [europepmc]
- CODA: quantitative 3D reconstruction of large tissues at cellular resolution. [europepmc]
- Neural Component of the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma. [europepmc]
- Activated Leukocyte Cell Adhesion Molecule (ALCAM), a Potential 'Seed' and 'Soil' Receptor in the Peritoneal Metastasis of Gastrointestinal Cancers. [europepmc]
- Tissue clearing and 3D reconstruction of digitized, serially sectioned slides provide novel insights into pancreatic cancer. [europepmc]
- Oncostatin-M and OSM-Receptor Feed-Forward Activation of MAPK Induces Separable Stem-like and Mesenchymal Programs. [europepmc]
- Progression of Site-specific Recurrence of Pancreatic Cancer and Implications for Treatment. [europepmc]
- Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor. [europepmc]
- Anatomical and Biological Considerations to Determine Resectability in Pancreatic Cancer. [europepmc]
- Surgery for Oligometastatic Pancreatic Cancer: Defining Biologic Resectability. [europepmc]
- Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. [europepmc]
- Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments. [europepmc]
Related